12:00 AM
Jun 29, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lantus insulin glargine: Post-marketing study data

Researchers from Cardiff University and colleagues performed a retrospective study of 62,809 diabetes patients in the U.K., concluding that those receiving insulin products were more likely to develop solid cancers than those on metformin. Insulin...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >